Syneos Health, Inc. - (SYNH): Price and Financial Metrics
SYNH Price/Volume Stats
| Current price | $42.98 | 52-week high | $52.23 |
| Prev. close | $42.97 | 52-week low | $22.89 |
| Day low | $42.97 | Volume | 7,386,200 |
| Day high | $42.99 | Avg. volume | 1,924,736 |
| 50-day MA | $42.60 | Dividend yield | N/A |
| 200-day MA | $39.40 | Market Cap | 4.46B |
SYNH Stock Price Chart Interactive Chart >
Syneos Health, Inc. - (SYNH) Company Bio
Syneos Health, formerly INC Research Holdings, provide the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The company was founded in 2010 and is based in Raleigh, North Carolina.
Latest SYNH News From Around the Web
Below are the latest news stories about SYNEOS HEALTH INC that investors may wish to consider to help them evaluate SYNH as an investment opportunity.
Syneos Health Closes Transaction with Private Investment FirmsTransaction Will Drive Ongoing Transformation and Accelerate Delivery of Tech-Enabled, Fit-for-Purpose Solutions to Biopharma CustomersMORRISVILLE, N.C., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced the completion of its acquisition by a consortium of private investment firm affiliates composed of Elliott Investment Management L.P., Patient Square Capital and Veritas |
Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600S&P SmallCap 600 constituent Civitas Resources Inc. (NYSE: CIVI) will replace Syneos Health Inc. (NASD: SYNH) in the S&P MidCap 400, and Hayward Holdings Inc. (NYSE: HAYW) will replace Civitas Resources in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 29. Elliot Investment Management is acquiring Syneos Health in a deal expected to be completed soon pending final conditions. |
Syneos Health Names Terttu Haring President, Clinical Sites & PatientsIndustry Veteran to Play Critical Role in Leading Global Clinical Operations, Cultivating Site Relationships, Empowering Patients and Shaping Innovative Clinical Trial SolutionsMORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical |
Syneos Health (SYNH) Declares Strategic Partnership With OracleSyneos Health (SYNH) announces an expanded collaboration with Oracle to accelerate patient recruitment capabilities. |
Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health EquityMORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic collaboration that will expand its relationship with Oracle. Using the Oracle Cerner Learning Health Network (LHN) and elements of Oracle’s suite of study startup solutions, the companies seek to help reduce the time it takes to recruit patients for clinical studies and increase the diversity of patient populations pa |
SYNH Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 0.56% |
| 3-year | -54.42% |
| 5-year | -21.38% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -64.28% |
| 2021 | 50.71% |
| 2020 | 14.55% |
| 2019 | 51.14% |
Continue Researching SYNH
Want to see what other sources are saying about Syneos Health Inc's financials and stock price? Try the links below:Syneos Health Inc (SYNH) Stock Price | Nasdaq
Syneos Health Inc (SYNH) Stock Quote, History and News - Yahoo Finance
Syneos Health Inc (SYNH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...